Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine

Published in the New England Journal of Medicine, this study examined population-based data from the Active Bacterial Core Surveillance of the Centers for Disease Control and Prevention to evaluate changes in the burden of invasive disease, defined by isolation of Streptococcus pneumoniae from a normally sterile site. Serotyping and susceptibility testing of isolates were performed. Trends were assessed using data from seven geographic areas with continuous participation from 1998 through 2001 (population, 16 million). The study concludes that the use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults. The vaccine provides an effective new tool for reducing disease caused by drug-resistant strains.

Author(s): Whitney C, Farley M, Hadler J, et al.

Published: 2003

  • Visit web page (English)

    (Located at content.nejm.org)

    Citation: Whitney C, Farley M, Hadler J, et al. Decline in Invasive Pneumococcal Disease After the Introduction of Protein-polysaccharide Conjugate Vaccine. New England Journal of Medicine. 2003;348(18):1737-1746.